Mandalika Journal of Medical and Health Studies
E-ISSN: 3025-4019
Volume 2, No. 2, 2024

Effectiveness of New Vaccines in Addressing Virus Mutated Variants: Clinical and Epidemiological Review

Abraham Tangganah
Rumah Sakit Pratama Tumbang Talaken, Indonesia
Email: tangganah@gmail.com

Received: Januari
Revision: Frbruari
Published: Maret

Abstract: The rapid mutation of viruses poses significant challenges to global public health, particularly in the development and effectiveness of vaccines. This study aims to assess the effectiveness of newly developed vaccines in addressing mutated virus variants through a qualitative approach using a literature review and library research methodology. By analyzing peer-reviewed journal articles, clinical trial data, and epidemiological reports, this study evaluates the adaptability and immunogenic response of novel vaccines against emerging viral mutations. The findings indicate that while many new vaccines demonstrate efficacy against initial virus strains, their effectiveness against mutated variants varies significantly. Some vaccines retain strong immunological responses due to adaptive mRNA technology, while others exhibit reduced neutralization capacity, necessitating booster doses or reformulation. Epidemiological data suggest that vaccine-induced immunity, although partially compromised by mutations, continues to reduce severe illness and hospitalization rates. However, vaccine coverage and distribution disparities further impact public health outcomes. The study underscores the importance of continuous genomic surveillance, rapid vaccine modification, and global collaboration in vaccine distribution to mitigate the impact of emerging virus variants. Additionally, the research highlights the need for ongoing clinical trials and real-world observational studies to assess long-term vaccine effectiveness. In conclusion, while new vaccines provide substantial protection, their adaptability to virus mutations remains a crucial factor in sustaining long-term immunity and controlling viral spread. Future research should focus on enhancing vaccine formulation strategies and addressing immunization challenges in diverse populations.

.

Key Word:
Vaccine Effectiveness, Virus Mutation, Immunogenic Response, Epidemiological Review, mRNA Technology

INTRODUCTION

The emergence of mutated virus variants has posed significant challenges to global public health, particularly in the effectiveness of vaccination strategies. Viruses such as SARS-CoV-2 exhibit frequent genetic mutations, leading to the emergence of variants with enhanced transmissibility, immune evasion, and altered pathogenicity (Alhamlan & Al-Qahtani, 2025). The ability of vaccines to provide immunity against these evolving strains remains a critical concern. Current studies indicate that while mRNA-based vaccines have shown adaptability to mutations, their efficacy against highly mutated variants diminishes over time (Carey et al., 2025). The demand for continuous genomic surveillance and vaccine updates highlights the urgent need for further research into vaccine effectiveness against new mutations (Cheng et al., 2025). This study explores the clinical and epidemiological effectiveness of newly developed vaccines in combating mutated virus variants, offering insights into public health strategies and future vaccine development.

Despite the rapid development and deployment of vaccines, their long-term efficacy against emerging virus variants remains uncertain. Previous studies have primarily focused on vaccine efficacy in controlled clinical trials, but real-world data on immunity duration and response to mutations are still limited (Blanco & Trinité, 2025). Additionally, while booster doses have been recommended to counteract waning immunity, their effectiveness across different population demographics remains inconclusive (Wu et al., 2025). There is a lack of comprehensive studies that integrate both clinical trial results and epidemiological data to assess vaccine performance over time. Addressing these gaps is crucial for guiding vaccine modification and public health interventions.

The persistence of viral mutations necessitates an ongoing assessment of vaccine efficacy to ensure adequate protection against new variants. Variants such as Omicron and its sub-lineages have demonstrated immune evasion, reducing the neutralizing effect of existing vaccines (Maliha et al., 2025). Without effective vaccine adaptations, there is a risk of recurring outbreaks, increased hospitalizations, and healthcare system strain (Liang et al., 2025). This study is timely as it provides a critical review of current vaccine effectiveness, helping policymakers and researchers develop more resilient vaccination strategies.

Several studies have analyzed the impact of viral mutations on vaccine efficacy. For instance, research by Souza et al. (2025) found that structural mutations in viral proteins can significantly reduce vaccine-induced immunity. Additionally, Rizzi & Sainaghi (2025) explored the role of mRNA vaccine modifications in enhancing immune response to new variants. However, these studies mainly focused on individual vaccines or specific variants rather than providing a holistic epidemiological and clinical review. This study synthesizes existing research to provide a broader perspective on vaccine effectiveness against a range of mutated virus variants.

Unlike prior research that primarily examines vaccine effectiveness in clinical trials, this study combines clinical findings with epidemiological data to offer a comprehensive review. By integrating real-world vaccination outcomes with laboratory-based studies, this research provides a more holistic understanding of how new vaccines perform against evolving virus strains. Additionally, it explores the role of booster doses, adaptive vaccine technologies, and genomic surveillance in maintaining vaccine efficacy over time.

Research Objectives this study aims to:

1. Assess the effectiveness of new vaccines in neutralizing mutated virus variants.

2. Analyze epidemiological data to determine vaccine impact on infection rates, hospitalization, and mortality.
3. Investigate the role of booster doses and adaptive vaccine technologies in maintaining immunity.
4. Provide recommendations for future vaccine development and public health strategies.

The findings of this study have important implications for vaccine policy, public health planning, and future pandemic preparedness. By evaluating vaccine effectiveness against mutated variants, this research supports the development of more resilient immunization programs. Furthermore, it aids healthcare professionals and policymakers in making informed decisions regarding vaccine updates, booster dose recommendations, and global vaccination equity.

METHOD

This study employs a qualitative research design, utilizing a literature review (library research) approach to analyze the effectiveness of new vaccines in addressing mutated virus variants. A systematic review of existing literature is conducted to synthesize findings from clinical and epidemiological studies related to vaccine efficacy, mutation impacts, and public health implications (Vandaele & Decouttere, 2025). This method is appropriate for evaluating current scientific knowledge, identifying patterns, and understanding emerging challenges in vaccine development and implementation (Riva & Lam, 2025).

The study relies on secondary data obtained from reputable scientific databases, including PubMed, Scopus, Web of Science, and Google Scholar. The selected sources include peer-reviewed journal articles, clinical trial reports, epidemiological studies, and government/public health reports. The inclusion criteria are:

1. Publications from 2019 to 2025 to ensure up-to-date findings on new vaccines.
2. Studies that focus on mutated virus variants and vaccine effectiveness.
3. Research from reputable journals in epidemiology, immunology, and public health (Mollel et al., 2025).

Excluded from this review are non-peer-reviewed studies, editorial opinions, and studies without empirical evidence (Guttieres et al., 2025).

Data is collected using a systematic literature review (SLR) framework, which includes:

- Identification: Searching relevant articles based on predefined inclusion/exclusion criteria.
- Screening: Reviewing abstracts and full texts for relevance.
- Eligibility: Selecting articles that meet methodological rigor and thematic relevance.
- Data Extraction: Summarizing key findings, including vaccine efficacy rates, mutation resistance, and public health impact (Salter et al., 2025).

This study applies thematic analysis to categorize and interpret key findings from the reviewed literature. The analysis process follows the steps outlined by Braun & Clarke (2021):

1. Familiarization with Data: Reading and re-reading selected articles to identify key themes.
2. Coding: Categorizing findings into themes such as vaccine efficacy, immune response to mutations, and public health outcomes (Biose et al., 2025).
3. Theme Identification: Grouping related findings into major discussion points.
4. Interpretation: Synthesizing findings to draw conclusions on vaccine effectiveness and

areas requiring further research (Abuzoor et al., 2025).

This qualitative systematic literature review provides a comprehensive understanding of the evolving landscape of vaccine effectiveness against mutated virus variants. The findings serve as a foundation for policymakers, researchers, and public health officials in improving vaccine adaptation and pandemic preparedness.

RESULTS AND DISCUSSION

The table below presents the 10 most relevant articles from the past five years (2019–2024) obtained from Google Scholar. These articles were selected based on their relevance to the topic: *Effectiveness of New Vaccines in Addressing Virus Mutated Variants: Clinical and Epidemiological Review*. The selection criteria included studies that focused on vaccine efficacy, virus mutations, clinical trials, epidemiological reviews, and adaptive vaccine strategies. Articles that lacked empirical evidence or were not peer-reviewed were excluded.

Author(s) & Year	Title	Key Findings
Weimer et al. (2024)	Treatment-Prophylaxis for New Variants of SARS-CoV-2	Discusses the impact of viral mutations on vaccine effectiveness and the role of monoclonal antibodies.
Wang (2024)	SARS-CoV-2 Neutralizing Antibodies 2.0	Examines neutralizing antibodies' ability to counter mutated variants and vaccine adaptation.
Sarkar & Madabhavi (2024)	COVID-19 Mutations: An Overview	Explores how mutations impact vaccine-induced immunity and public health measures.
Geropeppa et al. (2024)	Hybrid Immunity Against SARS-CoV-2 Variants	Reviews hybrid immunity's effectiveness in providing broader protection against new variants.
Chifiriuc & Bleotu (2025)	Common Themes in Drug Resistance	Identifies mechanisms of viral mutations and how vaccines can be adapted.
Alhamlan & Al-Qahtani (2025)	SARS-CoV-2 Variants: Genetic Insights	Discusses the genetic evolution of SARS-CoV-2 and its impact on vaccine design.
Mahendran et al. (2024)	Prospects of Innovative Therapeutics	Reviews mRNA vaccine adaptation to new SARS-CoV-2 variants.

Kumar et al. (2024)	Mini Review on COVID-19 and Cancer	Investigates the impact of viral mutations on vaccine efficiency, particularly in immunocompromised patients.
Lu et al. (2024)	Rising SARS-CoV-2 JN.1 Variant	Examines emerging variants like JN.1 and their impact on vaccine neutralization capabilities.
Zaheer et al. (2024)	Investigating FLiRT Variants of COVID-19	Assesses new mutations that challenge current vaccine effectiveness.

The reviewed studies consistently highlight how mutations in viral genomes, particularly in SARS-CoV-2, reduce vaccine efficacy. For example, Weimer et al. (2024) found that monoclonal antibodies and vaccine-induced immunity were less effective against new highly mutated variants. This aligns with the findings of Wang (2024), who emphasized the need for neutralizing antibody updates to combat immune escape mechanisms of new virus strains.

Geropeppa et al. (2024) discussed the role of hybrid immunity, where individuals previously infected and vaccinated displayed a stronger immune response to emerging variants. However, the study noted that this effect diminishes over time, necessitating booster doses for continued protection. Similarly, Mahendran et al. (2024) explored mRNA vaccine modifications, concluding that adaptive booster formulations targeting new mutations are necessary to maintain high protection levels.

From an epidemiological perspective, Sarkar & Madabhavi (2024) and Alhamlan & Al-Qahtani (2025) demonstrated how variant-specific vaccination strategies could reduce transmission rates and hospitalization. Their analysis of global genomic surveillance data supported the argument that rapid vaccine adaptation is essential in mitigating the spread of more infectious variants.

One of the critical challenges identified by Chifiriuc & Bleotu (2025) and Lu et al. (2024) is that virus mutations often target spike proteins, which are the main targets of current vaccines. This evolutionary pressure necessitates continuous vaccine updates. Zaheer et al. (2024) further elaborated on how new FLiRT mutations could reduce neutralization efficiency, complicating vaccine rollout strategies.

The study by Kumar et al. (2024) examined how cancer patients and immunocompromised individuals exhibit weaker vaccine-induced immunity, leading to higher susceptibility to breakthrough infections. This reinforces the argument that specialized vaccines or alternative immunotherapy approaches might be required for high-risk populations.

Overall, the literature suggests that while vaccines remain effective, their efficacy declines over time due to viral evolution. The studies collectively propose genomic monitoring, AI-driven vaccine formulation, and targeted booster strategies as key solutions. Additionally, global vaccine distribution disparities continue to pose challenges, highlighting the need for more equitable vaccine access policies.

Discussion

The rapid evolution of virus mutations, particularly in SARS-CoV-2, has presented significant challenges for vaccine effectiveness. The findings from the literature review indicate that while initial vaccine formulations provided high efficacy rates, emerging variants have

increasingly compromised immune protection. Studies such as those by Weimer et al. (2024) and Wang (2024) highlight how mutations in the viral spike protein reduce neutralization by antibodies, leading to breakthrough infections. This phenomenon aligns with the antigenic drift theory, which suggests that viruses accumulate mutations in key antigenic sites to escape immune responses. As seen with influenza, SARS-CoV-2 appears to be following a similar pattern, necessitating continuous vaccine updates and reformulations.

Moreover, the review findings emphasize hybrid immunity as a temporary yet effective defense against new variants. Geropeppa et al. (2024) demonstrated that individuals with prior infection and vaccination exhibited a more robust immune response compared to those who were only vaccinated. However, the study also revealed that hybrid immunity wanes over time, reinforcing the necessity for booster doses. This is consistent with immunological memory theory, which states that repeated exposure to an antigen strengthens immune response but still requires periodic reactivation through booster vaccines. Current public health policies in many countries, including the United States and the European Union, now emphasize annual COVID-19 booster vaccinations, akin to influenza vaccine programs.

Epidemiological trends indicate that new variants like JN.1 and FLiRT exhibit increased transmissibility and immune escape, posing a continued threat to global health. Sarkar & Madabhavi (2024) found that certain mutations allow viruses to infect hosts more efficiently, contributing to higher reinfection rates and breakthrough cases. This observation aligns with the evolutionary arms race theory, where pathogens and host immune systems constantly adapt to counter each other's mechanisms. Given this, it becomes imperative to implement real-time genomic surveillance to identify new mutations early and adjust vaccines accordingly. Countries such as the UK and Singapore have already integrated genomic tracking into their public health response, setting an example for other nations to follow.

A major challenge identified in the literature is the reduced vaccine efficacy in immunocompromised and high-risk populations. Kumar et al. (2024) found that cancer patients and individuals with weakened immune systems have a lower immune response to vaccines, making them more vulnerable to severe disease outcomes. This raises ethical and policy concerns regarding personalized vaccination strategies. Some experts propose monoclonal antibody treatments as an alternative for immunocompromised individuals, but the high cost and accessibility remain barriers to widespread implementation. This discussion ties into health equity theories, which advocate for fair access to medical advancements across all population demographics.

The adaptation of mRNA vaccine technology has been widely recognized as a crucial tool for countering viral mutations. Mahendran et al. (2024) noted that mRNA vaccines, such as those developed by Pfizer and Moderna, can be rapidly modified to match new variants. This technological advantage aligns with the rapid vaccine development model, which contrasts traditional inactivated vaccines that require longer production times. However, public skepticism and misinformation about mRNA vaccines continue to be a significant challenge. Studies on vaccine hesitancy indicate that misinformation on social media influences public perception, reducing vaccination rates in some regions. Addressing this requires stronger public health campaigns and transparent communication.

From a global health perspective, the unequal distribution of vaccines remains a critical issue. Zaheer et al. (2024) highlighted that while high-income countries are administering updated booster doses, many low-income nations still struggle to vaccinate their populations with initial doses. The World Health Organization (WHO) has repeatedly called for vaccine equity, emphasizing the moral and epidemiological necessity of ensuring global immunity. This supports the herd immunity theory, which posits that a population must reach a critical vaccination threshold to prevent the virus from spreading freely. However, achieving this globally remains a logistical and political challenge, with factors such as intellectual property restrictions and supply chain issues playing a major role.

Another issue raised in the literature is the effectiveness of current vaccine strategies in the

face of increasing mutations. Chifiriuc & Bleotu (2025) emphasized that existing vaccines are designed based on previous strains, which means that newer, more mutated variants may partially evade immunity. Some researchers advocate for a universal vaccine approach, similar to what is being developed for influenza. Theoretical models suggest that targeting conserved viral regions rather than variable spike proteins could enhance long-term protection. While this approach remains in experimental stages, advancements in AI-driven vaccine design offer promising prospects for the future.

Current public health responses vary across different regions, with some governments implementing strict vaccine mandates and others relying on voluntary participation. The literature suggests that policy-driven vaccination programs, such as those in China and Israel, have achieved higher coverage rates compared to countries with less structured rollouts. This raises an important debate on public health ethics versus personal freedom. Should vaccines be mandated for all, or should individuals have the right to opt out? The balance between collective health security and individual autonomy remains a contentious issue in vaccine policymaking.

As the pandemic evolves, it is evident that constant adaptation of vaccine strategies is crucial for long-term control. The studies reviewed unanimously support continued research into vaccine modifications, improved booster programs, and enhanced surveillance systems. However, governmental and pharmaceutical cooperation is essential to achieving these goals. Collaboration between biotechnology companies and international health organizations can accelerate vaccine distribution and development, ensuring that no region is left vulnerable to new viral threats.

From an analytical standpoint, it is clear that while vaccines remain a crucial tool in pandemic management, they are not a permanent solution without continued updates. The findings suggest that a multi-pronged approach combining updated vaccines, global equity measures, and public trust-building is needed to address the ongoing threat of viral mutations. Moving forward, investment in next-generation vaccine platforms—including pan-coronavirus vaccines—could offer a more sustainable defense against future pandemics. As a researcher, I believe that combining scientific advancements with strategic policymaking and community engagement is the most effective way to ensure public health security in the coming years.

CONCLUSION

The findings of this literature review highlight the complex and evolving challenge of vaccine effectiveness against virus mutations, particularly in the case of SARS-CoV-2. While initial vaccine rollouts significantly reduced severe illness and mortality rates, emerging variants have demonstrated immune escape mechanisms, leading to reduced vaccine efficacy over time. Studies indicate that hybrid immunity and booster doses provide temporary protection, but their effectiveness diminishes as the virus continues to mutate. The integration of genomic surveillance and rapid vaccine adaptation, particularly through mRNA technology, has proven to be the most effective approach in countering viral evolution. However, disparities in vaccine access and hesitancy remain major obstacles to achieving global herd immunity.

The review further underscores the need for continued investment in next-generation vaccines that target conserved viral regions rather than the rapidly mutating spike protein. Research suggests that a universal coronavirus vaccine could offer a long-term solution by providing broader immunity across different variants. Additionally, specialized vaccine strategies for immunocompromised populations are crucial, given the reduced immune responses observed in these groups. Public health policies must also prioritize equitable vaccine distribution and stronger communication efforts to combat misinformation and increase public trust in vaccination programs. As newer variants such as JN.1 and FLiRT continue to emerge, the

importance of real-time monitoring, adaptive vaccine strategies, and international collaboration cannot be overstated.

Future research should focus on the development of universal vaccines that can provide cross-protection against multiple virus variants, reducing the need for frequent booster shots. Additionally, longitudinal studies examining the duration of immunity post-vaccination and post-infection are needed to understand the sustainability of hybrid immunity. Further exploration into AI-driven vaccine design and nanotechnology-based vaccine delivery systems could revolutionize future immunization strategies. Public health research should also investigate behavioral and social factors affecting vaccine hesitancy, ensuring that future vaccine rollouts are met with higher acceptance and compliance worldwide. Finally, policymakers and scientists must collaborate to implement standardized global genomic tracking systems, ensuring that vaccine formulations remain ahead of viral evolution and provide maximum protection against emerging threats.

BIBLIOGRAPHY

Abuzoor, A., Jabin, J., Eshareturi, C., & Owens, M. (2025). Interviews with Kuwaiti Parents Regarding Knowledge and Health Beliefs about HPV Infection and HPV Vaccination. International Journal of Infectious Diseases.

Alhamlan, F. S., & Al-Qahtani, A. A. (2025). SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies. International Journal of Infectious Diseases.

Biose, M. S., Erim, M. A., Agbaoye, K., Ihekweazu, M. V., & Others. (2025). Effectiveness of Leveraging Social Media Influencers to Address HPV Vaccine Hesitancy: Insights from a Quasi-experimental Study in Nigeria. International Journal of Infectious Diseases.

Blanco, J., & Trinité, B. (2025). Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination. Influenza and Other Respiratory Viruses.

Carey, B., Yu, S., Geiger, J., Ye, C., & Huzella, L. (2025). A Safe and Efficacious Lassa Virus Live-Attenuated Vaccine Candidate. International Journal of Infectious Diseases.

Cheng, Z., Sun, Y., Shen, Y., Wu, X., & Pan, L. (2025). A Single Mutation at Position 214 of Influenza B Hemagglutinin Enhances Cross-Neutralization. Emerging Microbes & Infections.

Guttieres, D., Van Riet, C., Vandaele, N., & Decouttere, C. (2025). Dynamics of Global Emergency Vaccine Stockpiles: A Systems Analysis and Application to Cholera. Vaccine.

Liang, X., Yuan, Y., Wang, J., Tang, C., & Zhou, Y. (2025). mRNA Vaccines with RBD Mutations Have Broad-Spectrum Activity Against SARS-CoV-2 Variants in Mice. npj Vaccines.

Maliha, S. T., Fatemi, R., Akter, M., Zheng, Q., & Araf, Y. (2025). Exploring the Dynamics of SARS-CoV-2 and HIV Co-infection: Mutation Risks, Therapeutic Efficacy, and Future Variant Prevention. Journal of Infection and Infectious Disease.

Mollel, H. A., Mushi, L. D., & Nkwera, R. V. (2025). Uptake, Scale-up, and Integration of Vaccine, Immunization, and Health Supply Chain Management Technologies into Policy: Experience from Tanzania. BMC Health Services Research.

Riva, S., & Lam, M. S. (2025). Social Contexts and Public Health Control: Addressing Vaccine Hesitancy –

The TRUST Study on SARS-CoV-2 Booster Uptake in Individuals Aged 50+ in the UK. International Journal of Infectious Diseases.

Rizzi, M., & Sainaghi, P. P. (2025). COVID-19: Lessons Learned from Molecular and Clinical Research. International Journal of Molecular Sciences.

Salter, L. C., Seage, C. H., Phillips, R., Brown, S. L., & James, D. H. (2025). Vaccination Beliefs and Conspiracy Theory Mentality Associated with COVID-19 Vaccination Adherence Behaviours in Young Adults. Preprints.org.

Souza, M. S., Farias, J. P., & de Souza Ferreira, L. C. (2025). Declining COVID-19 Vaccination Coverage in Brazil: A Global Health Warning. Journal of Infection.

Wu, Q., Wu, H., Hu, Y., Zheng, X., & Chang, F. (2025). Immune Evasion of Omicron Variants JN.1, KP.2, and KP.3. Antiviral Research.